Journal of Oral Science Research ›› 2015, Vol. 31 ›› Issue (11): 1064-1068.

Previous Articles     Next Articles

Effects of Compound Skullcap Tablets on the Expression of OPG/RANKL in Human Periodontal Ligament Cells and Alveolar with Periodontitis.

ZHANG Jiang-lin, WANG Hao-yu, LI Dan, YANG Xiang-di, SHI Lei, LUO Ning, CHEN Yue.   

  1. Department of Periodontal and Oral Mucosal Diasease, Stomatology Hospital of Xi'an Jiaotong University College of Medicine, Xi'an 710004, China
  • Received:2015-06-16 Online:2015-11-28 Published:2016-03-21

Abstract: Objective: To investigate effects of compound skullcap tablets on the expression of OPG/RANKL in human periodontal ligament cells (hPDLCs) and alveolar with periodontitis in SD rats. Methods: hPDLCs were isolated and identified in vitro. ELISA was used to detect the effects of compound skullcap tablets on the expression of OPG/RANKL. Rat periodontitis model was constructed by injecting LPS locally, and immunohistochemistry was used to detect effects of compound skullcap tablets on the expression of OPG/RANKL of alveolar bone in vivo. Results: Compound skullcap tablets at the concentration of 0.2μg/ml could significantly reduce the expression of RANKL in hPDLCs in vitro (P<0.05), while the expression of OPG was not significantly changed, which led to an increased ratio of OPG/RANKL (P<0.05). Immunohistochemistry showed the highest expression level of OPG in treatment group (P<0.05) and the highest expression of RANKL in periodontitis rats. Conclusion: Compound skullcap tablets can increase the ratio of OPG/RANKL and may be used to treat periodontitis clinically in the future.

CLC Number: